<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00238628</url>
  </required_header>
  <id_info>
    <org_study_id>LUN0005</org_study_id>
    <secondary_id>80031</secondary_id>
    <secondary_id>IRUSIRES0436</secondary_id>
    <secondary_id>LUN0005</secondary_id>
    <nct_id>NCT00238628</nct_id>
  </id_info>
  <brief_title>A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase I/II Study of Bexarotene in Combination With ZD 1839 (IRESSA) in the Third Line Treatment of Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ligand Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      The purpose of Phase 1 of this study is to evaluate the safety of the combination regimen,&#xD;
      bexarotene and ZD1839. Phase II will evaluate the median survival, time to disease&#xD;
      progression, and toxicity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (RECIST CRITERIA), time to progression, toxicity</measure>
    <time_frame>Completed 9/2005</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic analysis</measure>
    <time_frame>Completed 12/2005</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Median survival</measure>
    <time_frame>Calculated Spring 2008</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate (RECIST CRITERIA), time to progression, toxicity</measure>
    <time_frame>Final analysis Spring 2008</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bexarotene</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iressa</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:- Patients must have histologically or cytologically confirmed NSCLC&#xD;
        which is stage IIIB with malignant pleural effusion or stage IV and have failed therapy&#xD;
        with at least a standard first line chemotherapy regimen, or be intolerant of standard&#xD;
        chemotherapy.&#xD;
&#xD;
          -  Patients may have non-measurable disease, or measurable disease, defined as at least&#xD;
             one lesion that can be accurately measured in at least one dimension (longest diameter&#xD;
             to be recorded) as &gt;20 mm with conventional techniques or as &gt;10 mm with spiral CT&#xD;
             scan).&#xD;
&#xD;
          -  Patients with asymptomatic or treated brain metastases will be eligible if they last&#xD;
             received therapy (including steroids) &gt; 4 weeks from study entry and are felt to have&#xD;
             a low likelihood of rapid deterioration from their brain metastases.&#xD;
&#xD;
          -  Patients must have had at least 1 prior systemic therapy for NSCLC, or have shown&#xD;
             intolerance to chemotherapy. Patients may not have received prior therapy with&#xD;
             bexarotene, ZD1839, or erlotinib (Tarceva).&#xD;
&#xD;
          -  At least 4 weeks must have elapsed from the time of major surgery and patients must&#xD;
             have recovered from the effects of any significant procedure.&#xD;
&#xD;
          -  A three week interval must have elapsed from the last dose of chemotherapy (30 days&#xD;
             for investigational therapy), prior to beginning protocol therapy (6 weeks if&#xD;
             nitrosoureas or mitomycin C). Palliative radiotherapy to bony sites of disease is&#xD;
             allowed while on trial and up to time of enrollment provided patient has no&#xD;
             significant side effects from the radiotherapy.&#xD;
&#xD;
          -  Age &gt;= 18 years.&#xD;
&#xD;
          -  Life expectancy &gt; 2 months.&#xD;
&#xD;
          -  ECOG performance status 0-2.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy test (serum ß HCG with&#xD;
             a sensitivity of at least 50 mlU/L) within 7 days prior to initiation of treatment and&#xD;
             must have used 2 reliable forms of effective contraception used simultaneously or have&#xD;
             been sexually abstinent for at least 4 weeks prior to the negative pregnancy test&#xD;
             through entry in the study. Should a woman become pregnant or suspect she is pregnant&#xD;
             while participating in this study, she should inform her treating physician&#xD;
             immediately.&#xD;
&#xD;
               -  Retinoid class agents are known teratogens.&#xD;
&#xD;
          -  Female patients and male patients with female partners of childbearing potential must&#xD;
             agree to sexual abstinence or to practice 2 reliable forms of effective contraception&#xD;
             used simultaneously during the entire period of bexarotene capsule treatment and for&#xD;
             at least 1 month after treatment is discontinued. Male patients must agree to use&#xD;
             condoms if they have a female sexual partner who is, or may become, pregnant.&#xD;
&#xD;
          -  Patients must have normal organ and marrow function as defined below:&#xD;
&#xD;
               -  leukocytes &gt;= 3,000/ul&#xD;
&#xD;
               -  absolute neutrophil count &gt;= 1,500/ul&#xD;
&#xD;
               -  platelets &gt;= 100,000/ul&#xD;
&#xD;
               -  total bilirubin within normal institutional limits&#xD;
&#xD;
               -  AST(SGOT)/ALT(SGPT) &lt;= 2.5 X institutional upper limit of normal&#xD;
&#xD;
               -  creatinine within normal institutional limits OR calculated creatinine clearance&#xD;
                  &gt;= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional&#xD;
                  normal&#xD;
&#xD;
               -  triglycerides and cholesterol levels which are within normal limits or&#xD;
                  &quot;normalized&quot; with medication&#xD;
&#xD;
          -  Patients may take the following agents, but with caution due to interactions with P450&#xD;
             metabolism: dexamethasone, protease inhibitors, ketoconazole and other azole&#xD;
             antifungals, erythromycin and other macrolides antibiotics, grapefruit juice, other&#xD;
             retinoid class drugs, beta-carotene compounds, and agents which enhance insulin&#xD;
             secretion and sensitivity. They may not take phenytoin, carbamazepine, rifampicin,&#xD;
             barbiturates, or St. John's Wort while on study.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
             Exclusion Criteria:- Insulin dependent diabetes&#xD;
&#xD;
          -  Thyroid disease&#xD;
&#xD;
          -  Patients may not have had chemotherapy within 3 weeks (6 weeks for nitrosoureas or&#xD;
             mitomycin C) prior to entering the study and must have recovered from adverse events&#xD;
             due to agents administered more than 4 weeks earlier. Palliative radiotherapy is&#xD;
             allowed to bony sites of disease.&#xD;
&#xD;
          -  Patients may not be receiving any other investigational agents or have received any&#xD;
             within 30 days prior to day 1 of study.&#xD;
&#xD;
          -  Patients with known symptomatic brain metastases are excluded from this clinical trial&#xD;
             because of their poor prognosis, those with treated, asymptomatic brain metastases are&#xD;
             eligible proved they have not required any therapy including steroids for at least 4&#xD;
             weeks.&#xD;
&#xD;
          -  Patients with a history of allergic reactions or sensitivity attributed to compounds&#xD;
             of similar chemical or biologic composition to bexarotene and ZD1839 are excluded.&#xD;
&#xD;
          -  Patients with triglycerides or cholesterol levels which are not within normal limits&#xD;
             or &quot;normalized&quot; with medication will be excluded.&#xD;
&#xD;
          -  Patients will be excluded for uncontrolled intercurrent illness including, but not&#xD;
             limited to, ongoing or active infection, symptomatic congestive heart failure,&#xD;
             unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations&#xD;
             that would limit compliance with study requirements.&#xD;
&#xD;
          -  Patients with another active malignancy except for non-melanoma skin cancers are&#xD;
             excluded.&#xD;
&#xD;
          -  Pregnant or breastfeeding women are excluded.&#xD;
&#xD;
          -  Patients with risk factors for pancreatitis are excluded such as a history of&#xD;
             pancreatitis, significant alcohol consumption or other factors which are deemed to put&#xD;
             them at high risk.&#xD;
&#xD;
          -  Patients taking systemic vitamin A in doses exceeding 15,000 IU/day within 14 days of&#xD;
             study entry will be excluded.&#xD;
&#xD;
          -  Patients who are unwilling to minimize exposure to ultraviolet light (sunlight) while&#xD;
             on bexarotene will be excluded.&#xD;
&#xD;
          -  Patients MAY NOT TAKE GEMFIBROZIL while on study due to interactions with bexarotene&#xD;
&#xD;
          -  Patients may not take phenytoin, carbamazepine, rifampicin, barbiturates, or St John's&#xD;
             Wort while on the study.&#xD;
&#xD;
          -  Patients with any evidence of clinically active interstitial lung disease will be&#xD;
             excluded (patients with chronic stable radiographic changes who are asymptomatic need&#xD;
             not be excluded)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charlotte D Jacobs</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <study_first_submitted>October 11, 2005</study_first_submitted>
  <study_first_submitted_qc>October 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2005</study_first_posted>
  <last_update_submitted>July 16, 2010</last_update_submitted>
  <last_update_submitted_qc>July 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Charlotte D Jacobs</name_title>
    <organization>Stanford University School of Medicine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bexarotene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

